Trade Summary

1 week ago, Betz Stephen F., serving as Chief Scientific Officer at Crinetics Pharmaceuticals, Inc. (CRNX), sold 10,612 shares at $37.37 per share, for a total transaction value of $396,610.00. Following this transaction, Betz Stephen F. now holds 137,101 shares of CRNX.

This sale represents a 7.00% decrease in Betz Stephen F.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, March 16, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, March 18, 2026, 2 days after the trade was made.

Crinetics Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.